Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Innovent Biologics Inc (OP: IVBXF ) 5.900 UNCHANGED Last Price Updated: 9:30 AM EDT, Oct 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 5.900 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 5.900 Today's Range 5.900 - 5.900 52wk Range 3.830 - 6.410 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal August 24, 2024 Shanghai Multitude Therapeutics out-licensed global rights for its Tissue Factor ADC to Adcendo in a $1 billion agreement. The value of the agreement includes upfront and milestone payments, with... Via Talk Markets Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal July 27, 2024 Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus... Via Talk Markets Performance YTD +9.26% +9.26% 1 Month -3.75% -3.75% 3 Month +10.28% +10.28% 6 Month +35.63% +35.63% 1 Year -0.67% -0.67% More News Read More Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma July 06, 2024 Via Talk Markets Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary June 30, 2024 Via Talk Markets Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings May 25, 2024 Via Talk Markets Week In Review: Sciwind, Sino Biological And Biocytogen Announce Deals May 11, 2024 Via Talk Markets Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion April 06, 2024 Via Talk Markets Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities March 23, 2024 Via Talk Markets Week In Review: EurekaBio Raises $40 Million To Support Lentiviral Vector Platform March 09, 2024 Via Talk Markets Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal March 02, 2024 Via Talk Markets Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership February 24, 2024 Via Talk Markets Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million February 11, 2024 Via Talk Markets Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal December 31, 2023 Via Talk Markets Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments December 02, 2023 Via Talk Markets Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion November 04, 2023 Via Talk Markets Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca August 26, 2023 Via Talk Markets Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration July 08, 2023 Via Talk Markets Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront July 01, 2023 Via Talk Markets Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas June 17, 2023 Via Talk Markets Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO June 10, 2023 Via Talk Markets Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC May 13, 2023 Via Talk Markets Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion February 18, 2023 Via Talk Markets Week In Review: Structure Stages $161 Million US IPO For AI/Structure-Based Drug Development February 04, 2023 Via Talk Markets Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific December 17, 2022 Via Talk Markets Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact December 10, 2022 Via Talk Markets Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.